Association of CYP2A6 gene polymorphisms with cigarette consumption: A meta-analysis

Drug and Alcohol Dependence

Volumn 149, Issue , 2015, Pages 268-271

  Pan, Lulu ^a   Yang, Xiaorong ^a   Li, Suyun ^a   Jia, Chongqi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cigarette; Cytochrome 2A6; Meta analysis; Smoking; Tobacco

Indexed keywords

CYTOCHROME P450 2A6;

AGE; AGE OF SMOKING INITIATION; ARTICLE; CYP2A6 GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; SMOKING; TOBACCO DEPENDENCE; ADOLESCENT; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; META ANALYSIS;

NICOTIANA TABACUM;

ADOLESCENT; AGE FACTORS; CYTOCHROME P-450 CYP2A6; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; SMOKING; TOBACCO USE DISORDER;

EID: 84926147828     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.01.032     Document Type: Article

References (28)

1. Benowitz N.L., Perez-Stable E.J., Herrera B., Jacob P. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J. Natl. Cancer Inst. 2002, 94:108-115.
2. Chenoweth M.J., O'Loughlin J., Sylvestre M.P., Tyndale R.F. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenet. Genomics 2013, 23:232-235.
3. Cholerton S., Arpanahi A., McCracken N., Boustead C., Taber H., Johnstone E., Leathart J., Daly A.K., Idle J.R. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994, 343:62-63.
4. Dempsey D., Tutka P., Jacob P., Allen F., Schoedel K., Tyndale R.F., Benowitz N.L. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 2004, 76:64-72.
5. Han S., Gelernter J., Luo X., Yang B.Z. Meta-analysis of 15 genome-wide linkage scans of smoking behavior. Biol. Psychiatry 2010, 67:12-19.
6. Harbord R.M., Egger M., Sterne J.A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med. 2006, 25:3443-3457.
7. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 1991, 86:1119-1127.
8. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
9. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br. Med. J. 2003, 327:557-560.
10. Ho M.K., Faseru B., Choi W.S., Nollen N.L., Mayo M.S., Thomas J.L., Okuyemi K.S., Ahluwalia J.S., Benowitz N.L., Tyndale R.F. Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol. Biomark. Prev. 2009, 18:3426-3434.
11. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 2005, 57:79-115.
12. Li M.D., Ma J.Z., Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin. Genet. 2004, 66:382-392.
13. Loriot M.A., Rebuissou S., Oscarson M., Cenee S., Miyamoto M., Ariyoshi N., Kamataki T., Hémon D., Beaune P., Stucker I. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001, 11:39-44.
14. Malaiyandi V., Lerman C., Benowitz N.L., Jepson C., Patterson F., Tyndale R.F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 2006, 11:400-409.
15. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1997, 282:1608-1614.
16. Minematsu N., Nakamura H., Furuuchi M., Nakajima T., Takahashi S., Tateno H., Ishizaka A. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur. Respir. J. 2006, 27:289-292.
17. O'Loughlin J., Paradis G., Kim W., DiFranza J., Meshefedjian G., McMillan-Davey E., Wong S., Hanley J., Tyndale R.F. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob. Control 2004, 13:422-428.
18. Oscarson M., McLellan R.A., Gullsten H., Yue Q.Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999, 448:105-110.
19. Patsopoulos N.A., Evangelou E., Ioannidis J.P. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int. J. Epidemiol. 2008, 37:1148-1157.
20. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E.M., Tyndale R.F. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 2000, 58:747-755.
21. Schoedel K.A., Hoffmann E.B., Rao Y., Sellers E.M., Tyndale R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004, 14:615-626.
22. Strasser A.A., Malaiyandi V., Hoffmann E., Tyndale R.F., Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob. Res. 2007, 9:511-518.
23. Tang D.W., Hello B., Mroziewicz M., Fellows L.K., Tyndale R.F., Dagher A. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage 2012, 60:2136-2143.
24. Thorgeirsson T.E., Gudbjartsson D.F., Surakka I., Vink J.M., Amin N., Geller F., Sulem P., Rafnar T., Esko T., Walter S., Gieger C., Rawal R., et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 2010, 42:448-453.
25. Tiihonen J., Pesonen U., Kauhanen J., Koulu M., Hallikainen T., Leskinen L., Salonen J.T. CYP2A6 genotype and smoking. Mol. Psychiatry 2000, 5:347-348.
26. Tyndale R.F., Sellers E.M. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther. Drug Monit. 2002, 24:163-171.
27. Wassenaar C.A., Dong Q., Wei Q., Amos C.I., Spitz M.R., Tyndale R.F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst. 2011, 103:1342-1346.
28. Zhu A.Z., Binnington M.J., Renner C.C., Lanier A.P., Hatsukami D.K., Stepanov I., Watson C.H., Sosnoff C.S., Benowitz N.L., Tyndale R.F. Alaska native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis 2013, 34:93-101.